– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has received CE Mark approval for its ...

Sky Medical Technology enters a distributor agreement with SMS Medical in the US to offer the geko� device for the elimination of edema (swelling) and blood clot (DVT) prevention following orthopaedic ...

ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has ...

Merck plans to launch US subcutaneous version of Keytruda on October 1 Healthcare & Pharmaceuticalscategory · 12:15 AM UTC · Updated ago The Merck logo ... US FDA approves first treatment ...

Sanofi's subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

March 28 (Reuters) - The U.S. Food and Drug Administration approved French drugmaker Sanofi's (SASY.PA), opens new tab hemophilia therapy, introducing a new type of treatment administered every ...

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare ...